Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results

Encouraging preclinical and translational data supporting DNase-based approaches to target NETs in difficult-to-treat cancers Strategic focus on investigator-initiated exploratory studies and institutional collaborations Continued progress toward IND-enabling activities for DNase I program Ended the year with $7.9 million of cash to fund operations FRAMINGHAM, MA / ACCESS Newswire / March 13, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the year ended December 31, 2025. Recent Highlights Expanded and presented preclinical and translational evidence supporting neutrophil extracellular traps (NETs) as drivers of cancer progression and highlighting the therapeutic potential of Deoxyribonuclease (DNase) -based interventions; Progressed investigator-initiated exploratory studies in Israel evaluating DNase I in combination with standard-of-care and immunotherapy platforms, including: Ongoing pancreatic ductal adenocarcinoma (PDAC) study; Proposed large B-cell lymphoma (LBCL) study in combination with Chimeric Antigen Receptor (CAR) T cell therapy; Advanced clinical manufacturing activities for DNase I toward Investigational New Drug (IND) application; Current focus on mechanism-of-action and translational research studies supported by encouraging CAR-T proof-of-concept studies with Scripps Research; and Pursuing strategic alternatives to maximize shareholder value.